Interní Med. 2013; 15(1): 5-10

Fenofibrate and its pharmaceutical formulations

MUDr.Jaromíra Gajdová¹, doc.MUDr.Karel Urbánek, Ph.D.²

¹ 2. interní klinika &ndash, gastroenterologická a hepatologická LF UP a Fakultní nemocnice Olomouc

² Ústav farmakologie LF UP a Fakultní nemocnice Olomouc

Fenofibrate belongs to the 3rd generation of fibrates and are one of the drugs of choice in pharmacotherapy of dyslipidemia. A number

of studies demonstrated a positive effect of fibrate therapy in the prevention of cardiovascular disease. Fenofibrate is used in patients

with mixed dyslipidemia with low HDL-cholesterol and high triglycerides. The mechanizm of their effect is delivered by activation of

lipoprotein lipase through expression of PPAR alpha receptors. The main problem with using fenofibrate is low solubility, which causes

uneven absorption. Therefore, new pharmaceutical formulations have been developed, which increase the surface of the product

and thus increase the solubility and bioavailability of fenofibrate. These formulations allow the use of fenofibrate without regard to

meals and thus improve patient compliance and the effect of therapy.

Keywords: dyslipidemia, fenofibrate, IDD-P, micronized form, nanoparticles, fenofibric acid

Published: January 15, 2013  Show citation